SCHEMBL11921952

CO[C@H]1OC(COS(=O)(=O)O)[C@@H](O[C@H]2C[C@H](O)[C@@H](O[C@@H]3OC(COS(=O)(=O)O)[C@@H](O[C@H]4C[C@H](O)[C@@H](O[C@@H]5OC(COS(=O)(=O)O)[C@@H](O[C@H]6C[C@H](O)[C@@H](O[C@@H]7OC(COS(=O)(=O)O)[C@@H](O[C@H]8C[C@H](O)[C@H](O)C(C)O8)[C@H](O)C7NSOOO)C(C)O6)[C@H](O)C5NSOOO)C(C)O4)[C@H](O)C3NSOOO)C(C)O2)[C@H](O)C1NSOOO

nearest known ligand 0.42

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	F10	P00742	2/20	0.42

▸	FGF1	P05230	4/20	0.34

▸	SERPINC1	P01008	2/20	0.32

▸	HPSE	Q9Y251	2/20	0.31

▸	F2	P00734	1/20	0.31

▸	STAT3	P40763	2/20	0.31

▸	FGF2	P09038	1/20	0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL11921950	0.97	F10 (0.41)	F10FGF1SERPINC1HPSESTAT3
SCHEMBL11921949	0.97	F10 (0.41)	F10FGF1SERPINC1HPSESTAT3
SCHEMBL11921948	0.97	F10 (0.41)	F10FGF1SERPINC1HPSESTAT3
SCHEMBL11921953	0.97	F10 (0.41)	F10FGF1SERPINC1HPSESTAT3
SCHEMBL11921951	0.97	F10 (0.41)	F10FGF1SERPINC1HPSESTAT3
SCHEMBL11921947	0.97	F10 (0.39)	F10FGF1SERPINC1STAT3FGF2
SCHEMBL11921943	0.90	F10 (0.38)	F10FGF1SERPINC1HPSEF2
SCHEMBL11921946	0.83	F10 (0.38)	F10FGF1
SCHEMBL11997512	0.82	F10 (0.39)	F10
SCHEMBL11997447	0.80	FGF1 (0.40)	F10FGF1SERPINC1HPSESTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9527930-B2	FGF receptor-activating N-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof	SANOFI (FR)	2016-12-27	—	—	US	disclosed
US-20120202769-A1	FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	SANOFI (FR)	2012-08-09	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120202769-A1	FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	FGFR1, FGF1, FGF2	F10 225/4885FGF1 2/4885SERPINC1 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.